Asthma is a common condition in which the airways in the lungs become narrowed, making it difficult to breathe. Asthma caused by allergies results from the immune system's over-reaction to inhaled allergen, and this immune system reaction prompts inflammation that causes the airway narrowing and other symptoms (i.e., wheezing, chest tightness, and cough). Xolair, which blocks this immune response, received U.S. Food and Drug Administration (FDA) approval in June 2003 and is the first anti-IgE agent for the treatment of patients at high risk from their allergy related asthma.
The severity of asthma varies from mild intermittent to severe persistent. Most asthma is effectively treated based on the National Heart, Lung and Blood Institute (NHLBI) clinical guidelines. Xolair can be beneficial as adjunctive therapy in patients whose symptoms are inadequately controlled despite the regular use of maximum dose inhaled corticosteroids.
Xolair is a recombinant DNA-derived humanized IgGl monoclonal antibody that selectively binds to the human immunoglobulin E (IgE) antibody. Xolair prevents IgE from attaching to the mast cell and its subsequent activation.
Xolair is administered subcutaneously once or twice a month, and in some cases more than one injection at a time.
Recommended FDA labeled dosing:
Xolair (omalizumab) is usually administered 150 to 375 mg by subcutaneous (SC) injection every 2 or 4 weeks. Dose(s) (mg) and dosing frequency is determined by serum total IgE level (IU/mL), measured before the start of treatment, and by body weight (kg).